A Cost-Effectiveness Analysis Of A Potential Biosimilar As A Primary Prophylactic Therapy Against Chemotherapy Induced Febrile Neutropenia For Breast Cancer Patients

No Thumbnail Available
Issue Date
Vaidya, Neel
This presentation aims at constructing a decision analytic model with the help of TreeAge software package to estimate a cost-effective measure (ICER – Incremental cost effectiveness ratio) for a proposed biosimilar in the US against chemotherapy induced febrile neutropenia for breast cancer patients. This measure of cost-effectiveness will be compared to two currently marketed biologicals, Filgrastim and Pegfilgrastim. A sensitivity analysis along with a probabilistic sensitivity analysis will be performed to test for the robustness of the model. This research aims at estimating whether the biosimilar will be a cost saving drug, as a prophylactic therapy, when it comes into the American market compared to the two current biologicals. With the economic burden of chemotherapy induced neutropenia being quite significant, estimating how the cost-effectiveness equation changes with a new biosimilar in the market is the central theme of this research. The Affordable Care Act of 2010 and the recent presidential elections of 2012 have given a lot of impetus on containing healthcare costs and effective utilization of economic resources. Hence, this form of economic evaluation and decision analysis is a vital segment of research contributing to impacting outcomes research in a big way. Expected Results: Biosimilar Filgrastim is expected to show a superior savings compared to the original Filgrastim biological, while the ICER between the biosimilar and Pegfilgrastim will have to be estimated and published after the model is run. Keywords: biosimilar, cost-effectiveness, febrile neutropenia, ICER, Filgrastim, Pegfilgrastim
Biology & Pharmoeconomics - Panel